Veli-Pekka Lehto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Veli-Pekka Lehto has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Olli Lohi
Tampere Center for Child, Adolescent, and Maternal Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
2 shared publications Anssi M. Poussu
Department of Pathology, University of Oulu, PO Box 5000 (Aapistie 5), Oulu FIN-90410, Finland
1 shared publicationAuli Linnala
† From the Department of Anatomy, University of Helsinki, Helsinki, Finland
1 shared publicationDia Kamel
From the Department of Pathology, University of Oulu, Oulu
1 shared publicationIsmo Virtanen
† From the Department of Anatomy, University of Helsinki, Helsinki, Finland
1 shared publicationJari Meriläinen
Biocenter Oulu and the Department of Pathology, University of Oulu, FIN-90220 Oulu, Finland
1 shared publication
Latest Publications
- 20 February 2001
- Published by Wiley in FEBS Letters
- Vol. 491 (1-2) , 1-3
EGF receptor: which way to go?
- 20 February 2001
- Published by Wiley in FEBS Letters
- Vol. 491 (1-2) , 1-3
EGF receptor: which way to go?
- 4 January 2001
- Published by Wiley in Muscle & Nerve
- Vol. 24 (1) , 127-129
Vear, a novel Golgi-associated protein, is preferentially expressed in type I cells in skeletal muscle
Vear is a novel Golgi‐associated protein with a domain structure characteristic of many vesicular transport–associated proteins. It has been suggested that Vear is involved in vesicle transport through trans‐Golgi. In this study, we have determined the localization of Vear in skeletal muscle. The staining for Vear in normal human muscle revealed a distribution pattern similar to that of type I fibers. We conclude that Vear is preferentially expressed in type I fibers in human muscle, presumably indicative of a specific function that remains to be identified. © 2001 John Wiley & Sons, Inc. Muscle Nerve 24: 127–129, 2001.
- 4 January 2001
- Published by Wiley in Muscle & Nerve
- Vol. 24 (1) , 127-129
Vear, a novel Golgi-associated protein, is preferentially expressed in type I cells in skeletal muscle
Vear is a novel Golgi‐associated protein with a domain structure characteristic of many vesicular transport–associated proteins. It has been suggested that Vear is involved in vesicle transport through trans‐Golgi. In this study, we have determined the localization of Vear in skeletal muscle. The staining for Vear in normal human muscle revealed a distribution pattern similar to that of type I fibers. We conclude that Vear is preferentially expressed in type I fibers in human muscle, presumably indicative of a specific function that remains to be identified. © 2001 John Wiley & Sons, Inc. Muscle Nerve 24: 127–129, 2001.
- Open Access
- 9 October 1998
- Published by Wiley in FEBS Letters
- Vol. 436 (3) , 419-423
EAST, a novel EGF receptor substrate, associates with focal adhesions and actin fibers
EAST is a novel epidermal growth factor receptor (EGFR) substrate. It interacts with Eps15, another EGFR substrate which is involved in receptor endocytosis. In this study we show that EAST associates with focal adhesions and actin filaments. First, in immunofluorescence and electron microscopy analysis, an extensive codistribution of EAST with vinculin, paxillin and actin filaments was seen. Second, overexpression of the NH2 terminus of EAST led to a formation of actin‐rich microspikes and membrane protrusions. Third, in cosedimentation assay EAST showed a direct association with actin. These results suggest that EAST is involved in the EGFR‐regulated reorganization of the actin cytoskeleton and may be part of a link between cytoskeleton and endocytic machinery.
- 9 October 1998
- Published by Wiley in FEBS Letters
- Vol. 436 (3) , 419-423
Open AccessEAST, a novel EGF receptor substrate, associates with focal adhesions and actin fibers
EAST is a novel epidermal growth factor receptor (EGFR) substrate. It interacts with Eps15, another EGFR substrate which is involved in receptor endocytosis. In this study we show that EAST associates with focal adhesions and actin filaments. First, in immunofluorescence and electron microscopy analysis, an extensive codistribution of EAST with vinculin, paxillin and actin filaments was seen. Second, overexpression of the NH2 terminus of EAST led to a formation of actin‐rich microspikes and membrane protrusions. Third, in cosedimentation assay EAST showed a direct association with actin. These results suggest that EAST is involved in the EGFR‐regulated reorganization of the actin cytoskeleton and may be part of a link between cytoskeleton and endocytic machinery.
- Open Access
- 7 August 1998
- Published by Wiley in FEBS Letters
- Vol. 432 (3) , 225-227
Src phosphorylates EAST, a novel EGF receptor‐associated protein
We have recently found and characterized EAST, a novel EGF receptor‐associated protein with SH3 and TAM domains. In this study we show that EAST becomes phosphorylated by Src kinase. This, in conjunction with our earlier observations on the close association between EAST and the endocytic machinery, suggests that EAST could be involved in Src‐dependent effects on EGF receptor endocytosis.
- 7 August 1998
- Published by Wiley in FEBS Letters
- Vol. 432 (3) , 225-227
Open AccessSrc phosphorylates EAST, a novel EGF receptor‐associated protein
We have recently found and characterized EAST, a novel EGF receptor‐associated protein with SH3 and TAM domains. In this study we show that EAST becomes phosphorylated by Src kinase. This, in conjunction with our earlier observations on the close association between EAST and the endocytic machinery, suggests that EAST could be involved in Src‐dependent effects on EGF receptor endocytosis.
- Open Access
- 1 September 1997
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 272 (37) , 23278-23284
FAP52, a Novel, SH3 Domain-containing Focal Adhesion Protein
- 1 September 1997
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 272 (37) , 23278-23284
Open AccessFAP52, a Novel, SH3 Domain-containing Focal Adhesion Protein
- Open Access
- 1 August 1993
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 100 (2) , 145-150
Tenascin Immunoreactivity in Lung Tumors
The distribution of tenascin immunoreactivity was analyzed in nonneoplastic lung tissue, benign lung tumors, and different types of lung carcinomas. In nonneoplastic lung tissue, tenascin could be observed in the basement membranes of the bronchial epithelium and endothelial cells, smooth muscle cells, and bronchial cartilage. Strong tenascin immunoreactivity was seen in the stroma of all the carcinomas of various histologic types. The staining intensity was stronger in the stroma of squamous cell carcinomas than in the stroma of the other types of lung carcinomas. In 10 of 27 squamous cell carcinomas, a granular intracytoplasmic reactivity could also be observed in a subpopulation of tumor cells. Similar intracytoplasmic reactivity was observed in 2 of 27 adenocarcinomas and in both adenosquamous carcinomas. In other types of lung tumors, individual cells did not have intracytoplasmic tenascin, except for one case of leiomyoma, which showed a weak, linear, intracytoplasmic tenascin reactivity. In lung hamartomas, tenascin could be seen in the cartilaginous component of the tumor and in the areas of basement membranes of the bronchial epithelium. In the carcinoid tumors, the stroma displayed a faint positivity for tenascin. These results show that tenascin is widely expressed in the stroma of lung carcinomas. A proportion of lung carcinomas also expressed intracytoplasmic tenascin immunoreactivity, suggesting that tumor cells may be able to synthesize tenascin. In the lung, tenascin positivity is not, however, restricted to malignant neoplasms, as evidenced by the presence of tenascin in nonneoplastic lung parenchyma and in some benign lung tumors.
- 1 August 1993
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 100 (2) , 145-150
Open AccessTenascin Immunoreactivity in Lung Tumors
The distribution of tenascin immunoreactivity was analyzed in nonneoplastic lung tissue, benign lung tumors, and different types of lung carcinomas. In nonneoplastic lung tissue, tenascin could be observed in the basement membranes of the bronchial epithelium and endothelial cells, smooth muscle cells, and bronchial cartilage. Strong tenascin immunoreactivity was seen in the stroma of all the carcinomas of various histologic types. The staining intensity was stronger in the stroma of squamous cell carcinomas than in the stroma of the other types of lung carcinomas. In 10 of 27 squamous cell carcinomas, a granular intracytoplasmic reactivity could also be observed in a subpopulation of tumor cells. Similar intracytoplasmic reactivity was observed in 2 of 27 adenocarcinomas and in both adenosquamous carcinomas. In other types of lung tumors, individual cells did not have intracytoplasmic tenascin, except for one case of leiomyoma, which showed a weak, linear, intracytoplasmic tenascin reactivity. In lung hamartomas, tenascin could be seen in the cartilaginous component of the tumor and in the areas of basement membranes of the bronchial epithelium. In the carcinoid tumors, the stroma displayed a faint positivity for tenascin. These results show that tenascin is widely expressed in the stroma of lung carcinomas. A proportion of lung carcinomas also expressed intracytoplasmic tenascin immunoreactivity, suggesting that tumor cells may be able to synthesize tenascin. In the lung, tenascin positivity is not, however, restricted to malignant neoplasms, as evidenced by the presence of tenascin in nonneoplastic lung parenchyma and in some benign lung tumors.